Gujarat Kidney Share Price Down 4% from Open Price

Gujarat Kidney & Super Speciality IPO opened for subscription on Dec 22, 2025, and ended on Dec 24, 2025. 

Gujarat Kidney IPO is a book-built public issue aggregating ₹250.80 crore, comprising only a fresh issue of 2.20 crore equity shares with no offer-for-sale component.

The IPO opened for subscription on December 22, 2025, and closed on December 24, 2025. The basis of allotment was finalised on December 26, 2025, and the shares are scheduled to list on both BSE and NSE on December 30, 2025.

The price band is fixed at ₹114 per share. Investors can apply in a lot size of 128 shares, requiring a minimum retail investment of ₹14,592, calculated at the upper end of the price band.

Gujarat Kidney IPO Subscription Update

The Gujarat Kidney IPO was oversubscribed 5.21 times overall. Breaking it down by category, the retail segment recorded a strong subscription of 19.04 times, the Qualified Institutional Buyers (QIB) segment excluding anchor investors was subscribed 1.06 times, and the Non-Institutional Investors (NII) segment saw a subscription of 5.73 times as of December 24, 2025, 6:19 PM (Day 3).

Gujarat Kidney Share Price

On the listing day, on the NSE, Gujarat Kidney share price (NSE: GKSL) opened at ₹120.00, up from its issue price of ₹114. At 10:43 AM, the share price was trading at ₹115.02, down by 4.75% from its open price and up by 0.26% from its issue price. As of the same time, the stock touched its day’s high at ₹123. The company’s market cap was ₹906.78 crore. 

On the BSE, at 10:44 AM, Gujarat Kidney share price was trading at ₹115.15, down by 4.64% from its opening price of ₹120.75 and 1.01% up from its issue price of ₹114.00.

About Gujarat Kidney & Super Speciality Limited

Founded in 2019, Gujarat Kidney and Super Speciality Limited (GKASSL) offers comprehensive multispeciality healthcare services, encompassing both secondary and tertiary care, across multiple locations in Gujarat, India.

The company manages seven multispeciality hospitals and four pharmacies, with a total bed capacity of 490, an approved capacity of 455, and an operational capacity of 340 beds.

GKASSL’s hospital network includes Gujarat Kidney and Superspeciality Hospital in Vadodara, Gujarat Multispeciality Hospital in Godhra, Raj Palmland Hospital Private Limited in Bharuch, Surya Hospital and ICU in Borsad, Gujarat Surgical Hospital in Vadodara, and Ashwini Medical Centre in Anand. The company also runs Ashwini Medical Store in Anand.

Services Provided

• Secondary Care Services: The hospitals provide general and surgical treatments for a wide range of medical conditions.
• Tertiary Care Services: GKASSL delivers advanced super speciality surgical procedures across multiple disciplines.

Gujarat Superspeciality Hospital offers specialised medical care in areas such as internal medicine, general surgery, minimally invasive procedures, orthopaedics and trauma treatment, joint replacement surgery, obstetrics and gynaecology, respiratory failure management, non-interventional cardiology, diabetology, and anaesthesiology.

As of June 30, 2025, the company employed 89 doctors, 332 nurses, and 338 support staff, ensuring comprehensive patient care across its facilities.

Also Read: Jio Platforms May Be Valued Up to US$170 Billion Ahead of IPO!

Conclusion

Gujarat Kidney shares debuted with a positive open but saw intraday volatility, reflecting cautious investor sentiment as the stock settles.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.